戴-薩克斯病市場：依疾病類型、治療方法、給藥途徑、最終用戶、分銷管道和地區分類

據估計，戴-薩克斯病市場在 2026 年的價值為 28.1 億美元，預計到 2033 年將達到 44 億美元。預計從 2026 年到 2033 年，其複合年成長率將達到 6.6%。

戴-薩克斯病是一種罕見的進行性神經退化性疾病，由己糖胺酶A缺乏引起，導致GM2神經節苷脂在神經細胞中積聚。這種體染色體隱性遺傳疾病主要影響嬰幼兒，造成嚴重的神經功能障礙，通常在出生後的最初幾年內導致死亡。全球戴-薩克斯病市場涵蓋治療性介入、診斷工具、酵素替代療法、基因療法以及旨在控制症狀和延緩疾病進展的支持性護理方案。

雖然這種疾病主要影響德系猶太人、法裔加拿大人和卡津人後裔，但隨著人們對該疾病認知的提高和基因篩檢技術的進步，全球市場正在不斷擴大。市場格局涵蓋了開發創新治療方法的製藥公司、提供帶因者篩檢和產前檢測的診斷實驗室，以及專門治療罕見遺傳疾病的醫療機構。目前的治療方法主要包括基材減少療法、酵素替代療法以及旨在解決潛在酵素缺陷的新型基因療法。此外，市場還包括用於支持症狀管理的安寧療護產品和服務，例如癲癇發作、飲食障礙和呼吸系統併發症，這反映了患者及其家屬對全面照護的需求。

市場動態

全球戴-薩克斯病市場正受到多項強勁因素的推動，包括人們對罕見遺傳疾病的認知不斷提高、診斷能力的提升以及對孤兒藥研發投入的增加。孤兒藥認定、延長市場獨佔期及加速核准流程等監管獎勵，正鼓勵製藥公司加強對這種極為罕見疾病的研發投入。遺傳諮詢和攜帶者篩檢計畫的日益普及，尤其是在高風險族群中，有助於早期診斷和市場擴張。此外，基因治療技術的進步，包括病毒載體療法和基因組編輯技術，作為極具前景的治療方法，正吸引大量的研究資金和商業性投資。

然而，該市場面臨諸多限制因素，主要原因是患者數量極少，限制了製藥公司的商業性可行性和投資回報。除了罕見疾病藥物研發成本高昂外，複雜的監管要求和漫長的臨床試驗流程也是市場准入的主要障礙。特殊治療方法的生產挑戰、某些地區醫療基礎設施不足以及疾病本身的嚴重性（往往導致過早死亡）進一步限制了市場成長。儘管存在這些挑戰，但新興市場仍蘊藏著機遇，例如醫療體系的不斷完善、學術機構與製藥公司合作的加強以及患者支持活動的拓展。疾病監測生物標記的開發、新生兒篩檢計畫的擴展以及潛在的聯合治療，都代表著進一步的市場機遇，有望推動未來成長並改善患者預後。

本次調查的主要特點

• 本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
• 此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略的重要見解。
• 本研究根據以下參數對全球戴-薩克斯病市場的主要參與者進行了分析：公司亮點、產品系列、主要特徵、財務表現和策略。
• 透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
• 這份全球戴-薩克斯病市場報告旨在為行業內的各種相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
• 透過對全球戴-薩克斯病市場進行分析時所使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。

目錄

第1章：研究目標與前提條件

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要

第3章：市場動態、監管與趨勢分析

• 市場動態
• 促進因素
• 抑制因子
• 機會
• 影響分析
• 主要進展
• 監管趨勢
• 產品上市及核准
• PEST分析
• 波特的分析
• 併購情景
• 產業趨勢

第4章 全球戴-薩克斯病市場：依疾病類型分類，2021-2033年

• 嬰兒戴-薩克斯病
• 晚髮型戴-薩克斯病

第5章 全球戴-薩克斯病市場：依治療類型分類，2021-2033年

• 基因治療
• N-乙醯-L-亮氨酸
• Benclusterat（基材減少療法）
• 其他正在研發中的藥物/治療方法

第6章 全球戴-薩克斯病市場：依給藥途徑分類，2021-2033年

• 口服
• 腸外
• 其他

第7章 全球戴-薩克斯病市場：依最終用戶分類，2021-2033年

• 醫院及神經科專科診所
• 診斷檢查室和遺傳中心
• 研究和學術機構
• 居家醫療
• 病人支持團體

第8章 全球戴-薩克斯病市場：依通路分類，2021-2033年

• 醫院藥房
• 零售藥房
• 網路藥房

第9章 全球戴-薩克斯病市場：依地區分類，2021-2033年

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲國家
• 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 其他亞太國家
• 中東
  • 海灣合作理事會國家
  • 以色列
  • 其他中東國家
• 非洲
  • 南非
  • 北非
  • 中非

第10章 競爭格局

• IntraBio Inc
• Recursion Pharmaceuticals, Inc.
• Forge Biologics
• Taysha Gene Therapies
• JCR Pharmaceuticals Co., Ltd.
• Sanofi
• Sio Gene Therapies

第11章 分析師建議

• 機會分析
• 分析師意見
• Coherent Opportunity Map

第12章 參考文獻與調查方法

• 參考
• 調查方法
• 關於本公司

Tay-Sachs Disease Market is estimated to be valued at USD 2.81 Bn in 2026 and is expected to reach USD 4.40 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.6% from 2026 to 2033.

Tay-Sachs disease represents a rare, progressive neurodegenerative disorder caused by deficiency of the hexosaminidase A enzyme, resulting in the accumulation of GM2 ganglioside in nerve cells. This autosomal recessive genetic condition primarily affects infants and children, leading to severe neurological deterioration and typically proving fatal within the first few years of life. The global Tay-Sachs disease market encompasses therapeutic interventions, diagnostic tools, enzyme replacement therapies, gene therapies, and supportive care solutions designed to manage symptoms and potentially alter disease progression.

While the condition predominantly occurs in individuals of Ashkenazi Jewish, French-Canadian, and Cajun descent, increased awareness and improved genetic screening have expanded market recognition worldwide. The market landscape includes pharmaceutical companies developing innovative treatment approaches, diagnostic laboratories offering carrier screening and prenatal testing, and healthcare providers specializing in rare genetic disorders. Current therapeutic focus centers on substrate reduction therapy, enzyme replacement therapy, and emerging gene therapy approaches that aim to address the underlying enzymatic deficiency. The market also encompasses palliative care products and services that help manage symptoms such as seizures, feeding difficulties, and respiratory complications, reflecting the comprehensive care requirements for affected patients and their families.

Market Dynamics

The global Tay-Sachs disease market is driven by several compelling factors, including increased awareness of rare genetic disorders, improved diagnostic capabilities, and growing investment in orphan drug development. Regulatory incentives such as orphan drug designation, extended market exclusivity periods, and accelerated approval pathways encourage pharmaceutical companies to invest in research and development for this ultra-rare condition. The rising prevalence of genetic counseling and carrier screening programs, particularly in high-risk populations, contributes to earlier diagnosis and market expansion. Additionally, advancements in gene therapy technologies, including viral vector-based approaches and genome editing techniques, present promising therapeutic avenues that attract significant research funding and commercial interest.

However, the market faces substantial restraints, primarily the extremely small patient population, which limits commercial viability and return on investment for pharmaceutical companies. The high cost of drug development for rare diseases, coupled with complex regulatory requirements and lengthy clinical trial processes, creates significant barriers to market entry. Manufacturing challenges for specialized therapies, limited healthcare infrastructure in certain regions, and the devastating nature of the disease that often results in early mortality further constrain market growth. Despite these challenges, opportunities exist in emerging markets with improving healthcare systems, increased collaboration between academic institutions and pharmaceutical companies, and growing patient advocacy efforts. The development of biomarkers for disease monitoring, expansion of newborn screening programs, and potential combination therapy approaches represent additional market opportunities that could drive future growth and improve patient outcomes.

Key Features of the Study

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global Tay-Sachs disease market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include IntraBio Inc, Recursion Pharmaceuticals, Inc., Forge Biologics, Taysha Gene Therapies, JCR Pharmaceuticals Co., Ltd., Sanofi, and Sio Gene Therapies.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global Tay-Sachs disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Tay-Sachs disease market

Market Segmentation

• Disease Type Insights (Revenue, USD Bn, 2021 - 2033)
• Infantile Tay-Sachs Disease
• Juvenile Tay-Sachs Disease
• Late-Onset Tay-Sachs Disease
• Treatment Type Insights (Revenue, USD Bn, 2021 - 2033)
• Gene Therapy
• N-Acetyl-L-Leucine
• Venglustat (Substrate Reduction Therapy)
• Other Pipeline Drugs/Therapy
• Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
• Oral
• Parenteral
• Others
• End User Insights (Revenue, USD Bn, 2021 - 2033)
• Hospitals and Specialty Neurology Clinics
• Diagnostic Laboratories and Genetic Centers
• Research and Academic Institutes
• Homecare Settings
• Patient Support Organizations
• Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
• IntraBio Inc
• Recursion Pharmaceuticals, Inc.
• Forge Biologics
• Taysha Gene Therapies
• JCR Pharmaceuticals Co., Ltd.
• Sanofi
• Sio Gene Therapies

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Tay-Sachs Disease Market, By Disease Type
  • Global Tay-Sachs Disease Market, By Treatment Type
  • Global Tay-Sachs Disease Market, By Route of Administration
  • Global Tay-Sachs Disease Market, By End User
  • Global Tay-Sachs Disease Market, By Distribution Channel
  • Global Tay-Sachs Disease Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Tay-Sachs Disease Market, By Disease Type, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Infantile Tay-Sachs Disease
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • Juvenile Tay-Sachs Disease
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Late-Onset Tay-Sachs Disease
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

5. Global Tay-Sachs Disease Market, By Treatment Type, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Gene Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• N-Acetyl-L-Leucine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Venglustat (substrate Reduction Therapy)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Other Pipeline Drugs/Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

6. Global Tay-Sachs Disease Market, By Route of Administration, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Parenteral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

7. Global Tay-Sachs Disease Market, By End User, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Hospitals and Specialty Neurology Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Diagnostic Laboratories and Genetic Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Research and Academic Institutes
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Homecare Settings
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Patient Support Organizations
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

8. Global Tay-Sachs Disease Market, By Distribution Channel, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

9. Global Tay-Sachs Disease Market, By Region, 2021 - 2033, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn) Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

10. Competitive Landscape

• IntraBio Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Recursion Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Forge Biologics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Taysha Gene Therapies
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• JCR Pharmaceuticals Co., Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sio Gene Therapies
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About Us